

Second Opinion

Case-Based Discussions Focused on the Management of Metastatic Prostate Cancer

CME INFORMATION

TARGET AUDIENCE

This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.

OVERVIEW OF ACTIVITY

Cancers of the genitourinary system affect hundreds of thousands of individuals within the United States each year, accounting for almost 30% of all newly diagnosed human cancers. Tumors of the prostate are definitively the most prevalent and are therefore the topic of extensive ongoing clinical research. Consequently, the clinical management of prostate cancer (PC) is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets of relevance to the continuous delivery of quality cross-functional care.

These video proceedings from a CME symposium held during the 2014 Genitourinary Cancers Symposium feature discussions with leading prostate cancer investigators regarding actual patient cases and related clinical research findings. By providing information on the latest research developments in the context of expert perspectives, this activity will assist medical and radiation oncologists, urologists and other healthcare professionals with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with PC.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

- Recall existing and emerging research information demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with chemotherapy-naïve or pretreated castration-resistant PC (CRPC), and use this information to guide treatment planning for these patients.
- Effectively apply evidence-based research findings in the administration of available immunotherapeutic, chemotherapeutic and secondary hormonal agents, alone or in combination, for patients with metastatic PC.

- Consider available Phase III clinical trial data documenting the efficacy of radium-223 dichloride in patients with PC and bone metastases, and formulate strategies to appropriately use this recently approved radiopharmaceutical agent.
- Assess available clinical and laboratory research evidence evaluating the impact of prior endocrine therapy exposure on the responsiveness of metastatic CRPC to cytotoxic interventions.
- Explore the emerging data and active research evaluating novel agents in the setting of PSA-only recurrent or advanced PC, and discuss the biologic basis for their clinical activity.
- Counsel appropriately selected patients with biochemically recurrent, asymptomatic and symptomatic metastatic PC about availability of and participation in ongoing clinical trials.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GUCancers14/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or

apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Tomasz M Beer, MD

Grover C Bagby Endowed Chair for Prostate Cancer Research
Professor of Medicine, Hematology and Medical Oncology
Deputy Director, OHSU Knight Cancer Institute
Portland, Oregon

Consulting Agreement: Dendreon Corporation; **Contracted Research:** Astellas, Bristol-Myers Squibb Company, Cougar Biotechnology Inc, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Janssen Biotech Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, OncoGenex Pharmaceuticals Inc.

Susan F Slovin, MD, PhD

Attending Physician
Genitourinary Oncology Service
Sidney Kimmel Center for Prostate and Urologic Cancers
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill-Cornell Medical College
New York, New York

Contracted Research: Astellas, Sanofi.

A Oliver Sartor, MD

Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana

Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; **Consulting Agreements:** Algeta ASA, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Biscayne Pharmaceuticals Inc, Medivation Inc, OncoGenex Pharmaceuticals Inc, Sanofi; **Contracted Research:** AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company, Progenics Pharmaceuticals Inc, Sanofi.

William K Oh, MD

Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
Mount Sinai School of Medicine
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, New York

Advisory Committee: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Janssen Pharmaceuticals Inc, Medivation Inc.

David I Quinn, MBBS, PhD

Medical Director, Norris Cancer Hospital and Clinics
Leader, Developmental Therapeutics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California

Advisory Committee: Amgen Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Prometheus Laboratories Inc, Teva Oncology, Veridex LLC; **Paid Research:** Millennium: The Takeda Oncology Company, Sanofi; **Other Remunerated Activities:** Medivation Inc, Teva Oncology.

CONSULTING MEDICAL ONCOLOGISTS — The following consulting medical oncologists (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Paul AS Fishkin, MD

Illinois CancerCare
Peoria, Illinois

Common Stock: Johnson & Johnson Pharmaceuticals, Novartis Pharmaceuticals Corporation.

Philip T Glynn, MD

Director, Medical OncologyMercy Medical Center
Director of Oncology
Noble Hospital
Assistant Clinical Professor
Tufts University School of Medicine
Springfield, Massachusetts

No real or apparent conflicts of interest to disclose.

Carl T Henningson Jr, MD

Regional Cancer Care Associates
Freehold, New Jersey

Speakers Bureau: Astellas, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Medivation Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Algeta US/Bayer HealthCare Pharmaceuticals, Astellas/Medivation Inc, Exelixis Inc, Millennium: The Takeda Oncology Company, Sanofi and Teva Oncology.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: May 2014

Expiration date: May 2015

SELECT PUBLICATIONS

Tomasz M Beer, MD

A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). NCT01212991

Lamb AD et al. **The transcriptional programme of the androgen receptor (AR) in prostate cancer.** *BJU Int* 2014;113(3):358-66.

Montgomery RB et al. **Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth.** *Cancer Res* 2008;68(11):4447-54.

Scher HI et al. **Increased survival with enzalutamide in prostate cancer after chemotherapy.** *N Engl J Med* 2012;367(13):1187-97.

Susan F Slovin, MD, PhD

Dreicer R et al. **Phase I/II trial of orteronel (TAK-700) — an investigational 17,20-lyase inhibitor — in patients with metastatic castration-resistant prostate cancer.** *Clin Cancer Res* 2014;20(5):1335-44.

A Oliver Sartor, MD

A phase III study of radium-223 dichloride in patients with symptomatic hormone refractory prostate cancer with skeletal metastases (ALSYMPCA). NCT00699751

Fizazi K et al. **Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study.** *Lancet* 2011;377(9768):813-22.

Fizazi K et al. **A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer.** *Proc ASCO* 2010;Abstract LBA4507.

Parker C et al. **Alpha emitter radium-223 and survival in metastatic prostate cancer.** *N Engl J Med* 2013;369(3):213-23.

William K Oh, MD

Badrising S et al. **Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.** *Cancer* 2013;120(7):968-75.

Bauer JA et al. **Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.** *Clin Cancer Res* 2010;16(2):681-90.

Mistry SJ et al. **New paradigms in microtubule-mediated endocrine signaling in prostate cancer.** *Mol Cancer Ther* 2013;12(5):555-66.

Petrylak DP et al. **Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.** *N Engl J Med* 2004;351(15):1513-20.

Tannock IF et al. **Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.** *N Engl J Med* 2004;351(15):1502-12.

Zhu F et al. **Mouse models for the p53 R72P polymorphism mimic human phenotypes.** *Cancer Res* 2010;70(14):5851-9.

David I Quinn MBBS, PhD

A study evaluating the pain palliation benefit of adding custirsen to docetaxel retreatment or cabazitaxel as second line therapy in men with metastatic castrate resistant prostate cancer (mCRPC). NCT01083615

A study of tasquinimod in men with metastatic castrate resistant prostate cancer. NCT01234311

Chi KN et al. **Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.** *J Clin Oncol* 2010;28(27):4247-54.

Comparison of cabazitaxel/prednisone alone or in combination with custirsen for 2nd line chemotherapy in prostate cancer (AFFINITY). NCT01578655

Comparison of docetaxel/prednisone to docetaxel/prednisone in combination with OGX-011 in men with prostate cancer (SYNERGY). NCT01188187

Hussain M et al. **Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.** *Proc ASCO* 2011;Abstract 4516.

Saad F et al. **Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.** *Clin Cancer Res* 2011;17(17):5765-73.

Study of cabozantinib (XL184) versus mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer (COMET-2). NCT01522443

Study of cabozantinib (XL184) versus prednisone in men with metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone or MDV3100. NCT01605227

Zoubeidi A et al. **Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.** *Clin Cancer Res* 2010;16(4):1088-93.